FLT3 and acute myeloid leukemia: MEN1703/SEL24 (MEN1703) is a first‐in‐class, oral, Type I dual PIM/FLT3 inhibitor that has been investigated as a single agent in a Phase 2 study in AML (DIAMOND‐01, NCT03008187).